Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Portfolio Pulse from
Nektar Therapeutics presented promising Phase 2 study results for NKTR-255, showing significant lymphocyte recovery in NSCLC patients post-chemoradiation. The study, presented at the SITC Annual Meeting, highlights NKTR-255's potential in enhancing NK cell proliferation and activation.
November 07, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nektar Therapeutics' NKTR-255 demonstrated significant lymphocyte recovery in NSCLC patients, potentially boosting the company's stock due to positive clinical trial results.
The positive Phase 2 study results for NKTR-255, showing significant lymphocyte recovery and NK cell activation, are likely to boost investor confidence in Nektar Therapeutics. This could lead to a short-term increase in stock price as the market reacts to the potential of NKTR-255 in treating NSCLC patients.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100